

Global Single-target Anti-VEGF Drugs Market Growth 2026-2032

<https://marketpublishers.com/r/G85449964D00EN.html>

Date: July 2026

Pages: 87

Price: US\$ 3,660.00 (Single User License)

ID: G85449964D00EN

Abstracts

The global Single-target Anti-VEGF Drugs market size is predicted to grow from US\$ million in 2025 to US\$ million in 2032; it is expected to grow at a CAGR of % from 2026 to 2032.

Single-target anti-VEGF drugs are medications designed to specifically block the action of vascular endothelial growth factor (VEGF) in the eye. VEGF plays a crucial role in promoting the growth of abnormal blood vessels, which can lead to vision-threatening conditions such as wet age-related macular degeneration (AMD), diabetic retinopathy, and macular edema.

United States market for Single-target Anti-VEGF Drugs is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

China market for Single-target Anti-VEGF Drugs is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

Europe market for Single-target Anti-VEGF Drugs is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

Global key Single-target Anti-VEGF Drugs players cover Roche, Novartis, Coherus BioSciences, Regeneron Pharmaceuticals, Samsung Bioepis, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.

LP Information, Inc. (LPI) ' newest research report, the 'Single-target Anti-VEGF Drugs Industry Forecast' looks at past sales and reviews total world Single-target Anti-VEGF Drugs sales in 2025, providing a comprehensive analysis by region and market sector

of projected Single-target Anti-VEGF Drugs sales for 2026 through 2032. With Single-target Anti-VEGF Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Single-target Anti-VEGF Drugs industry.

This Insight Report provides a comprehensive analysis of the global Single-target Anti-VEGF Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Single-target Anti-VEGF Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Single-target Anti-VEGF Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Single-target Anti-VEGF Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Single-target Anti-VEGF Drugs.

This report presents a comprehensive overview, market shares, and growth opportunities of Single-target Anti-VEGF Drugs market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

Aflibercept

Conbercept

Ranibizumab

Brolucizumab

Faricimab

Other

Segmentation by Application:

Age-related Macular Degeneration

Diabetic Retinopathy

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Roche

Novartis

Coherus BioSciences

Regeneron Pharmaceuticals

Samsung Bioepis

Biocon Biologics

Chengdu Kanghong Pharmaceutical

Key Questions Addressed in this Report

What is the 10-year outlook for the global Single-target Anti-VEGF Drugs market?

What factors are driving Single-target Anti-VEGF Drugs market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Single-target Anti-VEGF Drugs market opportunities vary by end market size?

How does Single-target Anti-VEGF Drugs break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Single-target Anti-VEGF Drugs Annual Sales 2021-2032
 - 2.1.2 World Current & Future Analysis for Single-target Anti-VEGF Drugs by Geographic Region, 2021, 2025 & 2032
 - 2.1.3 World Current & Future Analysis for Single-target Anti-VEGF Drugs by Country/Region, 2021, 2025 & 2032
- 2.2 Single-target Anti-VEGF Drugs Segment by Type
 - 2.2.1 Aflibercept
 - 2.2.2 Conbercept
 - 2.2.3 Ranibizumab
 - 2.2.4 Brolucizumab
 - 2.2.5 Faricimab
 - 2.2.6 Other
 - 2.2.7 Single-target Anti-VEGF Drugs Sales by Type
 - 2.2.7.1 Global Single-target Anti-VEGF Drugs Sales Market Share by Type (2021-2026)
 - 2.2.7.2 Global Single-target Anti-VEGF Drugs Revenue and Market Share by Type (2021-2026)
 - 2.2.7.3 Global Single-target Anti-VEGF Drugs Sale Price by Type (2021-2026)
- 2.3 Single-target Anti-VEGF Drugs Segment by Application
 - 2.3.1 Age-related Macular Degeneration
 - 2.3.2 Diabetic Retinopathy
 - 2.3.3 Other
 - 2.3.4 Single-target Anti-VEGF Drugs Sales by Application

2.3.4.1 Global Single-target Anti-VEGF Drugs Sale Market Share by Application (2021-2026)

2.3.4.2 Global Single-target Anti-VEGF Drugs Revenue and Market Share by Application (2021-2026)

2.3.4.3 Global Single-target Anti-VEGF Drugs Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

3.1 Global Single-target Anti-VEGF Drugs Breakdown Data by Company

3.1.1 Global Single-target Anti-VEGF Drugs Annual Sales by Company (2021-2026)

3.1.2 Global Single-target Anti-VEGF Drugs Sales Market Share by Company (2021-2026)

3.2 Global Single-target Anti-VEGF Drugs Annual Revenue by Company (2021-2026)

3.2.1 Global Single-target Anti-VEGF Drugs Revenue by Company (2021-2026)

3.2.2 Global Single-target Anti-VEGF Drugs Revenue Market Share by Company (2021-2026)

3.3 Global Single-target Anti-VEGF Drugs Sale Price by Company

3.4 Key Manufacturers Single-target Anti-VEGF Drugs Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Single-target Anti-VEGF Drugs Product Location Distribution

3.4.2 Players Single-target Anti-VEGF Drugs Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR SINGLE-TARGET ANTI-VEGF DRUGS BY GEOGRAPHIC REGION

4.1 World Historic Single-target Anti-VEGF Drugs Market Size by Geographic Region (2021-2026)

4.1.1 Global Single-target Anti-VEGF Drugs Annual Sales by Geographic Region (2021-2026)

4.1.2 Global Single-target Anti-VEGF Drugs Annual Revenue by Geographic Region (2021-2026)

4.2 World Historic Single-target Anti-VEGF Drugs Market Size by Country/Region (2021-2026)

4.2.1 Global Single-target Anti-VEGF Drugs Annual Sales by Country/Region

(2021-2026)

4.2.2 Global Single-target Anti-VEGF Drugs Annual Revenue by Country/Region

(2021-2026)

4.3 Americas Single-target Anti-VEGF Drugs Sales Growth

4.4 APAC Single-target Anti-VEGF Drugs Sales Growth

4.5 Europe Single-target Anti-VEGF Drugs Sales Growth

4.6 Middle East & Africa Single-target Anti-VEGF Drugs Sales Growth

5 AMERICAS

5.1 Americas Single-target Anti-VEGF Drugs Sales by Country

5.1.1 Americas Single-target Anti-VEGF Drugs Sales by Country (2021-2026)

5.1.2 Americas Single-target Anti-VEGF Drugs Revenue by Country (2021-2026)

5.2 Americas Single-target Anti-VEGF Drugs Sales by Type (2021-2026)

5.3 Americas Single-target Anti-VEGF Drugs Sales by Application (2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Single-target Anti-VEGF Drugs Sales by Region

6.1.1 APAC Single-target Anti-VEGF Drugs Sales by Region (2021-2026)

6.1.2 APAC Single-target Anti-VEGF Drugs Revenue by Region (2021-2026)

6.2 APAC Single-target Anti-VEGF Drugs Sales by Type (2021-2026)

6.3 APAC Single-target Anti-VEGF Drugs Sales by Application (2021-2026)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Single-target Anti-VEGF Drugs by Country

7.1.1 Europe Single-target Anti-VEGF Drugs Sales by Country (2021-2026)

- 7.1.2 Europe Single-target Anti-VEGF Drugs Revenue by Country (2021-2026)
- 7.2 Europe Single-target Anti-VEGF Drugs Sales by Type (2021-2026)
- 7.3 Europe Single-target Anti-VEGF Drugs Sales by Application (2021-2026)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa Single-target Anti-VEGF Drugs by Country
 - 8.1.1 Middle East & Africa Single-target Anti-VEGF Drugs Sales by Country (2021-2026)
 - 8.1.2 Middle East & Africa Single-target Anti-VEGF Drugs Revenue by Country (2021-2026)
- 8.2 Middle East & Africa Single-target Anti-VEGF Drugs Sales by Type (2021-2026)
- 8.3 Middle East & Africa Single-target Anti-VEGF Drugs Sales by Application (2021-2026)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

- 10.1 Raw Material and Suppliers
- 10.2 Manufacturing Cost Structure Analysis of Single-target Anti-VEGF Drugs
- 10.3 Manufacturing Process Analysis of Single-target Anti-VEGF Drugs
- 10.4 Industry Chain Structure of Single-target Anti-VEGF Drugs

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Single-target Anti-VEGF Drugs Distributors

11.3 Single-target Anti-VEGF Drugs Customer

12 WORLD FORECAST REVIEW FOR SINGLE-TARGET ANTI-VEGF DRUGS BY GEOGRAPHIC REGION

12.1 Global Single-target Anti-VEGF Drugs Market Size Forecast by Region

12.1.1 Global Single-target Anti-VEGF Drugs Forecast by Region (2027-2032)

12.1.2 Global Single-target Anti-VEGF Drugs Annual Revenue Forecast by Region (2027-2032)

12.2 Americas Forecast by Country (2027-2032)

12.3 APAC Forecast by Region (2027-2032)

12.4 Europe Forecast by Country (2027-2032)

12.5 Middle East & Africa Forecast by Country (2027-2032)

12.6 Global Single-target Anti-VEGF Drugs Forecast by Type (2027-2032)

12.7 Global Single-target Anti-VEGF Drugs Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

13.1 Roche

13.1.1 Roche Company Information

13.1.2 Roche Single-target Anti-VEGF Drugs Product Portfolios and Specifications

13.1.3 Roche Single-target Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

13.1.4 Roche Main Business Overview

13.1.5 Roche Latest Developments

13.2 Novartis

13.2.1 Novartis Company Information

13.2.2 Novartis Single-target Anti-VEGF Drugs Product Portfolios and Specifications

13.2.3 Novartis Single-target Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

13.2.4 Novartis Main Business Overview

13.2.5 Novartis Latest Developments

13.3 Coherus BioSciences

13.3.1 Coherus BioSciences Company Information

13.3.2 Coherus BioSciences Single-target Anti-VEGF Drugs Product Portfolios and Specifications

13.3.3 Coherus BioSciences Single-target Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

13.3.4 Coherus BioSciences Main Business Overview

13.3.5 Coherus BioSciences Latest Developments

13.4 Regeneron Pharmaceuticals

13.4.1 Regeneron Pharmaceuticals Company Information

13.4.2 Regeneron Pharmaceuticals Single-target Anti-VEGF Drugs Product Portfolios and Specifications

13.4.3 Regeneron Pharmaceuticals Single-target Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

13.4.4 Regeneron Pharmaceuticals Main Business Overview

13.4.5 Regeneron Pharmaceuticals Latest Developments

13.5 Samsung Bioepis

13.5.1 Samsung Bioepis Company Information

13.5.2 Samsung Bioepis Single-target Anti-VEGF Drugs Product Portfolios and Specifications

13.5.3 Samsung Bioepis Single-target Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

13.5.4 Samsung Bioepis Main Business Overview

13.5.5 Samsung Bioepis Latest Developments

13.6 Biocon Biologics

13.6.1 Biocon Biologics Company Information

13.6.2 Biocon Biologics Single-target Anti-VEGF Drugs Product Portfolios and Specifications

13.6.3 Biocon Biologics Single-target Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

13.6.4 Biocon Biologics Main Business Overview

13.6.5 Biocon Biologics Latest Developments

13.7 Chengdu Kanghong Pharmaceutical

13.7.1 Chengdu Kanghong Pharmaceutical Company Information

13.7.2 Chengdu Kanghong Pharmaceutical Single-target Anti-VEGF Drugs Product Portfolios and Specifications

13.7.3 Chengdu Kanghong Pharmaceutical Single-target Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

13.7.4 Chengdu Kanghong Pharmaceutical Main Business Overview

13.7.5 Chengdu Kanghong Pharmaceutical Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Single-target Anti-VEGF Drugs Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Table 2. Single-target Anti-VEGF Drugs Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of Aflibercept

Table 4. Major Players of Conbercept

Table 5. Major Players of Ranibizumab

Table 6. Major Players of Brolucizumab

Table 7. Major Players of Faricimab

Table 8. Major Players of Other

Table 9. Global Single-target Anti-VEGF Drugs Sales by Type (2021-2026) & (K Units)

Table 10. Global Single-target Anti-VEGF Drugs Sales Market Share by Type (2021-2026)

Table 11. Global Single-target Anti-VEGF Drugs Revenue by Type (2021-2026) & (\$ million)

Table 12. Global Single-target Anti-VEGF Drugs Revenue Market Share by Type (2021-2026)

Table 13. Global Single-target Anti-VEGF Drugs Sale Price by Type (2021-2026) & (US\$/Unit)

Table 14. Global Single-target Anti-VEGF Drugs Sale by Application (2021-2026) & (K Units)

Table 15. Global Single-target Anti-VEGF Drugs Sale Market Share by Application (2021-2026)

Table 16. Global Single-target Anti-VEGF Drugs Revenue by Application (2021-2026) & (\$ million)

Table 17. Global Single-target Anti-VEGF Drugs Revenue Market Share by Application (2021-2026)

Table 18. Global Single-target Anti-VEGF Drugs Sale Price by Application (2021-2026) & (US\$/Unit)

Table 19. Global Single-target Anti-VEGF Drugs Sales by Company (2021-2026) & (K Units)

Table 20. Global Single-target Anti-VEGF Drugs Sales Market Share by Company (2021-2026)

Table 21. Global Single-target Anti-VEGF Drugs Revenue by Company (2021-2026) & (\$ millions)

Table 22. Global Single-target Anti-VEGF Drugs Revenue Market Share by Company (2021-2026)

Table 23. Global Single-target Anti-VEGF Drugs Sale Price by Company (2021-2026) & (US\$/Unit)

Table 24. Key Manufacturers Single-target Anti-VEGF Drugs Producing Area Distribution and Sales Area

Table 25. Players Single-target Anti-VEGF Drugs Products Offered

Table 26. Single-target Anti-VEGF Drugs Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 27. New Products and Potential Entrants

Table 28. Market M&A Activity & Strategy

Table 29. Global Single-target Anti-VEGF Drugs Sales by Geographic Region (2021-2026) & (K Units)

Table 30. Global Single-target Anti-VEGF Drugs Sales Market Share Geographic Region (2021-2026)

Table 31. Global Single-target Anti-VEGF Drugs Revenue by Geographic Region (2021-2026) & (\$ millions)

Table 32. Global Single-target Anti-VEGF Drugs Revenue Market Share by Geographic Region (2021-2026)

Table 33. Global Single-target Anti-VEGF Drugs Sales by Country/Region (2021-2026) & (K Units)

Table 34. Global Single-target Anti-VEGF Drugs Sales Market Share by Country/Region (2021-2026)

Table 35. Global Single-target Anti-VEGF Drugs Revenue by Country/Region (2021-2026) & (\$ millions)

Table 36. Global Single-target Anti-VEGF Drugs Revenue Market Share by Country/Region (2021-2026)

Table 37. Americas Single-target Anti-VEGF Drugs Sales by Country (2021-2026) & (K Units)

Table 38. Americas Single-target Anti-VEGF Drugs Sales Market Share by Country (2021-2026)

Table 39. Americas Single-target Anti-VEGF Drugs Revenue by Country (2021-2026) & (\$ millions)

Table 40. Americas Single-target Anti-VEGF Drugs Sales by Type (2021-2026) & (K Units)

Table 41. Americas Single-target Anti-VEGF Drugs Sales by Application (2021-2026) & (K Units)

Table 42. APAC Single-target Anti-VEGF Drugs Sales by Region (2021-2026) & (K Units)

Table 43. APAC Single-target Anti-VEGF Drugs Sales Market Share by Region (2021-2026)

Table 44. APAC Single-target Anti-VEGF Drugs Revenue by Region (2021-2026) & (\$ millions)

Table 45. APAC Single-target Anti-VEGF Drugs Sales by Type (2021-2026) & (K Units)

Table 46. APAC Single-target Anti-VEGF Drugs Sales by Application (2021-2026) & (K Units)

Table 47. Europe Single-target Anti-VEGF Drugs Sales by Country (2021-2026) & (K Units)

Table 48. Europe Single-target Anti-VEGF Drugs Revenue by Country (2021-2026) & (\$ millions)

Table 49. Europe Single-target Anti-VEGF Drugs Sales by Type (2021-2026) & (K Units)

Table 50. Europe Single-target Anti-VEGF Drugs Sales by Application (2021-2026) & (K Units)

Table 51. Middle East & Africa Single-target Anti-VEGF Drugs Sales by Country (2021-2026) & (K Units)

Table 52. Middle East & Africa Single-target Anti-VEGF Drugs Revenue Market Share by Country (2021-2026)

Table 53. Middle East & Africa Single-target Anti-VEGF Drugs Sales by Type (2021-2026) & (K Units)

Table 54. Middle East & Africa Single-target Anti-VEGF Drugs Sales by Application (2021-2026) & (K Units)

Table 55. Key Market Drivers & Growth Opportunities of Single-target Anti-VEGF Drugs

Table 56. Key Market Challenges & Risks of Single-target Anti-VEGF Drugs

Table 57. Key Industry Trends of Single-target Anti-VEGF Drugs

Table 58. Single-target Anti-VEGF Drugs Raw Material

Table 59. Key Suppliers of Raw Materials

Table 60. Single-target Anti-VEGF Drugs Distributors List

Table 61. Single-target Anti-VEGF Drugs Customer List

Table 62. Global Single-target Anti-VEGF Drugs Sales Forecast by Region (2027-2032) & (K Units)

Table 63. Global Single-target Anti-VEGF Drugs Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 64. Americas Single-target Anti-VEGF Drugs Sales Forecast by Country (2027-2032) & (K Units)

Table 65. Americas Single-target Anti-VEGF Drugs Annual Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 66. APAC Single-target Anti-VEGF Drugs Sales Forecast by Region (2027-2032)

& (K Units)

Table 67. APAC Single-target Anti-VEGF Drugs Annual Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 68. Europe Single-target Anti-VEGF Drugs Sales Forecast by Country (2027-2032) & (K Units)

Table 69. Europe Single-target Anti-VEGF Drugs Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 70. Middle East & Africa Single-target Anti-VEGF Drugs Sales Forecast by Country (2027-2032) & (K Units)

Table 71. Middle East & Africa Single-target Anti-VEGF Drugs Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 72. Global Single-target Anti-VEGF Drugs Sales Forecast by Type (2027-2032) & (K Units)

Table 73. Global Single-target Anti-VEGF Drugs Revenue Forecast by Type (2027-2032) & (\$ millions)

Table 74. Global Single-target Anti-VEGF Drugs Sales Forecast by Application (2027-2032) & (K Units)

Table 75. Global Single-target Anti-VEGF Drugs Revenue Forecast by Application (2027-2032) & (\$ millions)

Table 76. Roche Basic Information, Single-target Anti-VEGF Drugs Manufacturing Base, Sales Area and Its Competitors

Table 77. Roche Single-target Anti-VEGF Drugs Product Portfolios and Specifications

Table 78. Roche Single-target Anti-VEGF Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 79. Roche Main Business

Table 80. Roche Latest Developments

Table 81. Novartis Basic Information, Single-target Anti-VEGF Drugs Manufacturing Base, Sales Area and Its Competitors

Table 82. Novartis Single-target Anti-VEGF Drugs Product Portfolios and Specifications

Table 83. Novartis Single-target Anti-VEGF Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 84. Novartis Main Business

Table 85. Novartis Latest Developments

Table 86. Coherus BioSciences Basic Information, Single-target Anti-VEGF Drugs Manufacturing Base, Sales Area and Its Competitors

Table 87. Coherus BioSciences Single-target Anti-VEGF Drugs Product Portfolios and Specifications

Table 88. Coherus BioSciences Single-target Anti-VEGF Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 89. Coherus BioSciences Main Business

Table 90. Coherus BioSciences Latest Developments

Table 91. Regeneron Pharmaceuticals Basic Information, Single-target Anti-VEGF Drugs Manufacturing Base, Sales Area and Its Competitors

Table 92. Regeneron Pharmaceuticals Single-target Anti-VEGF Drugs Product Portfolios and Specifications

Table 93. Regeneron Pharmaceuticals Single-target Anti-VEGF Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 94. Regeneron Pharmaceuticals Main Business

Table 95. Regeneron Pharmaceuticals Latest Developments

Table 96. Samsung Bioepis Basic Information, Single-target Anti-VEGF Drugs Manufacturing Base, Sales Area and Its Competitors

Table 97. Samsung Bioepis Single-target Anti-VEGF Drugs Product Portfolios and Specifications

Table 98. Samsung Bioepis Single-target Anti-VEGF Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 99. Samsung Bioepis Main Business

Table 100. Samsung Bioepis Latest Developments

Table 101. Biocon Biologics Basic Information, Single-target Anti-VEGF Drugs Manufacturing Base, Sales Area and Its Competitors

Table 102. Biocon Biologics Single-target Anti-VEGF Drugs Product Portfolios and Specifications

Table 103. Biocon Biologics Single-target Anti-VEGF Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 104. Biocon Biologics Main Business

Table 105. Biocon Biologics Latest Developments

Table 106. Chengdu Kanghong Pharmaceutical Basic Information, Single-target Anti-VEGF Drugs Manufacturing Base, Sales Area and Its Competitors

Table 107. Chengdu Kanghong Pharmaceutical Single-target Anti-VEGF Drugs Product Portfolios and Specifications

Table 108. Chengdu Kanghong Pharmaceutical Single-target Anti-VEGF Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 109. Chengdu Kanghong Pharmaceutical Main Business

Table 110. Chengdu Kanghong Pharmaceutical Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Single-target Anti-VEGF Drugs
- Figure 2. Single-target Anti-VEGF Drugs Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Single-target Anti-VEGF Drugs Sales Growth Rate 2021-2032 (K Units)
- Figure 7. Global Single-target Anti-VEGF Drugs Revenue Growth Rate 2021-2032 (\$ millions)
- Figure 8. Single-target Anti-VEGF Drugs Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Figure 9. Single-target Anti-VEGF Drugs Sales Market Share by Country/Region (2025)
- Figure 10. Single-target Anti-VEGF Drugs Sales Market Share by Country/Region (2021, 2025 & 2032)
- Figure 11. Product Picture of Aflibercept
- Figure 12. Product Picture of Conbercept
- Figure 13. Product Picture of Ranibizumab
- Figure 14. Product Picture of Brolucizumab
- Figure 15. Product Picture of Faricimab
- Figure 16. Product Picture of Other
- Figure 17. Global Single-target Anti-VEGF Drugs Sales Market Share by Type in 2026
- Figure 18. Global Single-target Anti-VEGF Drugs Revenue Market Share by Type (2021-2026)
- Figure 19. Single-target Anti-VEGF Drugs Consumed in Age-related Macular Degeneration
- Figure 20. Global Single-target Anti-VEGF Drugs Market: Age-related Macular Degeneration (2021-2026) & (K Units)
- Figure 21. Single-target Anti-VEGF Drugs Consumed in Diabetic Retinopathy
- Figure 22. Global Single-target Anti-VEGF Drugs Market: Diabetic Retinopathy (2021-2026) & (K Units)
- Figure 23. Single-target Anti-VEGF Drugs Consumed in Other
- Figure 24. Global Single-target Anti-VEGF Drugs Market: Other (2021-2026) & (K Units)
- Figure 25. Global Single-target Anti-VEGF Drugs Sale Market Share by Application (2025)
- Figure 26. Global Single-target Anti-VEGF Drugs Revenue Market Share by Application in 2026

Figure 27. Single-target Anti-VEGF Drugs Sales by Company in 2026 (K Units)

Figure 28. Global Single-target Anti-VEGF Drugs Sales Market Share by Company in 2026

Figure 29. Single-target Anti-VEGF Drugs Revenue by Company in 2026 (\$ millions)

Figure 30. Global Single-target Anti-VEGF Drugs Revenue Market Share by Company in 2026

Figure 31. Global Single-target Anti-VEGF Drugs Sales Market Share by Geographic Region (2021-2026)

Figure 32. Global Single-target Anti-VEGF Drugs Revenue Market Share by Geographic Region in 2026

Figure 33. Americas Single-target Anti-VEGF Drugs Sales 2021-2026 (K Units)

Figure 34. Americas Single-target Anti-VEGF Drugs Revenue 2021-2026 (\$ millions)

Figure 35. APAC Single-target Anti-VEGF Drugs Sales 2021-2026 (K Units)

Figure 36. APAC Single-target Anti-VEGF Drugs Revenue 2021-2026 (\$ millions)

Figure 37. Europe Single-target Anti-VEGF Drugs Sales 2021-2026 (K Units)

Figure 38. Europe Single-target Anti-VEGF Drugs Revenue 2021-2026 (\$ millions)

Figure 39. Middle East & Africa Single-target Anti-VEGF Drugs Sales 2021-2026 (K Units)

Figure 40. Middle East & Africa Single-target Anti-VEGF Drugs Revenue 2021-2026 (\$ millions)

Figure 41. Americas Single-target Anti-VEGF Drugs Sales Market Share by Country in 2026

Figure 42. Americas Single-target Anti-VEGF Drugs Revenue Market Share by Country (2021-2026)

Figure 43. Americas Single-target Anti-VEGF Drugs Sales Market Share by Type (2021-2026)

Figure 44. Americas Single-target Anti-VEGF Drugs Sales Market Share by Application (2021-2026)

Figure 45. United States Single-target Anti-VEGF Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 46. Canada Single-target Anti-VEGF Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 47. Mexico Single-target Anti-VEGF Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 48. Brazil Single-target Anti-VEGF Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 49. APAC Single-target Anti-VEGF Drugs Sales Market Share by Region in 2026

Figure 50. APAC Single-target Anti-VEGF Drugs Revenue Market Share by Region (2021-2026)

Figure 51. APAC Single-target Anti-VEGF Drugs Sales Market Share by Type (2021-2026)

Figure 52. APAC Single-target Anti-VEGF Drugs Sales Market Share by Application (2021-2026)

Figure 53. China Single-target Anti-VEGF Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 54. Japan Single-target Anti-VEGF Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 55. South Korea Single-target Anti-VEGF Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 56. Southeast Asia Single-target Anti-VEGF Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 57. India Single-target Anti-VEGF Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 58. Australia Single-target Anti-VEGF Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 59. China Taiwan Single-target Anti-VEGF Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 60. Europe Single-target Anti-VEGF Drugs Sales Market Share by Country in 2026

Figure 61. Europe Single-target Anti-VEGF Drugs Revenue Market Share by Country (2021-2026)

Figure 62. Europe Single-target Anti-VEGF Drugs Sales Market Share by Type (2021-2026)

Figure 63. Europe Single-target Anti-VEGF Drugs Sales Market Share by Application (2021-2026)

Figure 64. Germany Single-target Anti-VEGF Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 65. France Single-target Anti-VEGF Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 66. UK Single-target Anti-VEGF Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 67. Italy Single-target Anti-VEGF Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 68. Russia Single-target Anti-VEGF Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 69. Middle East & Africa Single-target Anti-VEGF Drugs Sales Market Share by Country (2021-2026)

Figure 70. Middle East & Africa Single-target Anti-VEGF Drugs Sales Market Share by Type (2021-2026)

Figure 71. Middle East & Africa Single-target Anti-VEGF Drugs Sales Market Share by Application (2021-2026)

Figure 72. Egypt Single-target Anti-VEGF Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 73. South Africa Single-target Anti-VEGF Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 74. Israel Single-target Anti-VEGF Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 75. Turkey Single-target Anti-VEGF Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 76. GCC Countries Single-target Anti-VEGF Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 77. Manufacturing Cost Structure Analysis of Single-target Anti-VEGF Drugs in 2026

Figure 78. Manufacturing Process Analysis of Single-target Anti-VEGF Drugs

Figure 79. Industry Chain Structure of Single-target Anti-VEGF Drugs

Figure 80. Channels of Distribution

Figure 81. Global Single-target Anti-VEGF Drugs Sales Market Forecast by Region (2027-2032)

Figure 82. Global Single-target Anti-VEGF Drugs Revenue Market Share Forecast by Region (2027-2032)

Figure 83. Global Single-target Anti-VEGF Drugs Sales Market Share Forecast by Type (2027-2032)

Figure 84. Global Single-target Anti-VEGF Drugs Revenue Market Share Forecast by Type (2027-2032)

Figure 85. Global Single-target Anti-VEGF Drugs Sales Market Share Forecast by Application (2027-2032)

Figure 86. Global Single-target Anti-VEGF Drugs Revenue Market Share Forecast by Application (2027-2032)

I would like to order

Product name: Global Single-target Anti-VEGF Drugs Market Growth 2026-2032

Product link: <https://marketpublishers.com/r/G85449964D00EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G85449964D00EN.html>